Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 176

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Effects of Lowering LDL Cholesterol on Progression of Kidney Disease

Open access
Haynes, Richard, Lewis, David, Emberson, Jonathan, Reith, Christina, Agodoa, Lawrence, Cass, Alan, Craig, Jonathan C., de Zeeuw, Dick, Feldt-Rasmussen, Bo, Fellström, Bengt, Levin, Adeera, Wheeler, David C., Walker, Rob, Herrington, William G., Baigent, Colin, Landray, Martin J., Baigent, Colin, Landray, Martin J., Reith, Christina, Emberson, Jonathan, Wheeler, David C., Tomson, Charles, Wanner, Christoph, Krane, Vera, Cass, Alan, Craig, Jonathan, Neal, Bruce, Jiang, Lixin, Hooi, Lai Seong, Levin, Adeera, Agodoa, Lawrence, Gaziano, Mike, Kasiske, Bertram, Walker, Rob, Massy, Ziad A., Feldt-Rasmussen, Bo, Krairittichai, Udom, Ophascharoensuk, Vuddidhej, Fellström, Bengt, Holdaas, Hallvard, Tesar, Vladimir, Wiecek, Andrzej, Grobbee, Diederick, de Zeeuw, Dick, Grönhagen-Riska, Carola, Dasgupta, Tanaji, Lewis, David, Herrington, Will, Mafham, Marion, Majoni, William, Wallendszus, Karl, Grimm, Richard, Pedersen, Terje, Tobert, Jonathan, Armitage, Jane, Baxter, Alex, Bray, Christopher, Chen, Yiping, Chen, Zhengming, Hill, Michael, Knott, Carol, Parish, Sarah, Simpson, David, Sleight, Peter, Young, Alan, Collins, Rory · 2014 · Journal of the American Society of Nephrology

Abstract

Lowering LDL cholesterol reduces the risk of developing atherosclerotic events in CKD, but the effects of such treatment on progression of kidney disease remain uncertain. Here, 6245 participants with CKD (not on dialysis) were randomly assigned to simvastatin (20 mg) plus ezetimibe (10 mg) daily or matching placebo. The main prespecified renal outcome was ESRD (defined as the initiation of maintenance dialysis or kidney transplantation). During 4.8 years of follow-up, allocation to simvastatin plus ezetimibe resulted in an average LDL cholesterol difference (SEM) of 0.96 (0.02) mmol/L compared with placebo. There was a nonsignificant 3% reduction in the incidence of ESRD (1057 [33.9%] cases with simvastatin plus ezetimibe versus 1084 [34.6%] cases with placebo; rate ratio, 0.97; 95% confidence interval [95% CI], 0.89 to 1.05; P=0.41). Similarly, allocation to simvastatin plus ezetimibe had no significant effect on the prespecified tertiary outcomes of ESRD or death (1477 [47.4%] events with treatment versus 1513 [48.3%] events with placebo; rate ratio, 0.97; 95% CI, 0.90 to 1.04; P=0.34) or ESRD or doubling of baseline creatinine (1189 [38.2%] events with treatment versus 1257 [40.2%] events with placebo; rate ratio, 0.93; 95% CI, 0.86 to 1.01; P=0.09). Exploratory analyses also showed no significant effect on the rate of change in eGFR. Lowering LDL cholesterol by 1 mmol/L did not slow kidney disease progression within 5 years in a wide range of patients with CKD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1681/asn.2013090965

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 176

Metadata

Authors
Haynes, R., Lewis, D., Emberson, J., Reith, C., Agodoa, L., Cass, A., Craig, J. C., de Zeeuw, D., Feldt-Rasmussen, B., Fellström, B., Levin, A., Wheeler, D. C., Walker, R., Herrington, W. G., Baigent, C., Landray, M. J., Baigent, C., Landray, M. J., Reith, C., Emberson, J., Wheeler, D. C., Tomson, C., Wanner, C., Krane, V., Cass, A., Craig, J., Neal, B., Jiang, L., Hooi, L. S., Levin, A., Agodoa, L., Gaziano, M., Kasiske, B., Walker, R., Massy, Z. A., Feldt-Rasmussen, B., Krairittichai, U., Ophascharoensuk, V., Fellström, B., Holdaas, H., Tesar, V., Wiecek, A., Grobbee, D., de Zeeuw, D., Grönhagen-Riska, C., Dasgupta, T., Lewis, D., Herrington, W., Mafham, M., Majoni, W., Wallendszus, K., Grimm, R., Pedersen, T., Tobert, J., Armitage, J., Baxter, A., Bray, C., Chen, Y., Chen, Z., Hill, M., Knott, C., Parish, S., Simpson, D., Sleight, P., Young, A., & Collins, R.
Venue
Journal of the American Society of Nephrology
Published
2014-08
Volume
25
Issue
8
Pages
1825-1833
ISSN
1046-6673 (ISSN-L)
OpenAlex
W2139664471
Cited by
176
References
8
FWCI
15.40
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of Lowering LDL Cholesterol on Progression of Kidney Disease. https://app.cochat.ai/papers/10.1681/asn.2013090965
The paper
Haynes, R., Lewis, D., Emberson, J., Reith, C., Agodoa, L., Cass, A., Craig, J. C., de Zeeuw, D., Feldt-Rasmussen, B., Fellström, B., Levin, A., Wheeler, D. C., Walker, R., Herrington, W. G., Baigent, C., Landray, M. J., Baigent, C., Landray, M. J., Reith, C., . . . Collins, R. (2014). Effects of Lowering LDL Cholesterol on Progression of Kidney Disease. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.2013090965

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.